MedPath

Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients

Not Applicable
Recruiting
Conditions
Lung Cancer - Non Small Cell
EGFR Exon 19 Deletion Mutation
Registration Number
NCT06659458
Lead Sponsor
Our Lady of the Lake Hospital
Brief Summary

EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
20
Inclusion Criteria
  • 18-100 years old
  • Biologically born female
  • Diagnosed with EGFR positive lung cancer (Arm 1-Cancer group)
  • No cancer diagnosis (Arm 2-health control)
Exclusion Criteria
  • less than 18 years of age
  • Biologically born male
  • Incarcerated at the time of participation

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Differences in DNA sequence of EGFR geneFrom enrollment to end of data analysis at 6 months

Subjects who have EGFR positive lung cancer will have their gene sequence compared to those that are EGFR negative and do not have lung cancer to look for differences in the sequence.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Our Lady of the Lake Regional Medical Center

🇺🇸

Baton Rouge, Louisiana, United States

© Copyright 2025. All Rights Reserved by MedPath